• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

    1.715 +0.115 (+7.19%)
    Streaming Delayed Price Updated: 2:32 PM EST, Jan 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,318,160
    Open 1.630
    Bid (Size) 1.710 (19,900)
    Ask (Size) 1.720 (31,200)
    Prev. Close 1.600
    Today's Range 1.611 - 1.730
    52wk Range 0.8621 - 3.780
    Shares Outstanding 142,183,418
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
    On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
    Issued on behalf of Oncolytics Biotech Inc. 
    From Equity Insider
    Via GlobeNewswire

    Performance

    YTD
    +27.0%
    +27.0%
    1 Month
    +16.7%
    +16.7%
    3 Month
    +41.7%
    +41.7%
    6 Month
    +3.3%
    +3.3%
    1 Year
    -6.8%
    -6.8%

    More News

    Read More
    The market is filled with gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
    Via The Motley Fool
    Topics Death Regulatory Compliance
    News headline image
    What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗
    Via The Motley Fool
    Topics Death Regulatory Compliance
    News headline image
    Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance
    Via MarketMinute
    Topics Bonds ETFs World Trade
    News headline image
    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    News headline image
    This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics Announces Participation in Upcoming Investor Conference
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Allogene Q2 Cash Tops $300 Million ↗
    Via The Motley Fool
    News headline image
    Allogene Narrows Loss in Fiscal Q2 ↗
    Via The Motley Fool
    News headline image
    Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    A Look at Allogene Therapeutics's Upcoming Earnings Report ↗
    Via Benzinga
    News headline image
    Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 13, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
    Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
    The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
    What is the current price of Allogene Therapeutics, Inc. - Common Stock?
    The current price of Allogene Therapeutics, Inc. - Common Stock is 1.715
    When was Allogene Therapeutics, Inc. - Common Stock last traded?
    The last trade of Allogene Therapeutics, Inc. - Common Stock was at 01/22/26 02:32 PM ET
    What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
    The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 243.84M
    How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
    Allogene Therapeutics, Inc. - Common Stock has 244M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.